A Look At CONMED (CNMD) Valuation After GI Exit, Guidance Raise And Debt Refinancing

Simply Wall St.

Jun 05

CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2641145296"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2641145296\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2641145296?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","is_english":true,"pubTime":"2026-06-05 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641145296","market":"nz","top_or_hot":-1,"title":"A Look At CONMED (CNMD) Valuation After GI Exit, Guidance Raise And Debt Refinancing","media":"Simply Wall St.","content":"<div>\n<p>CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/a-look-at-conmed-cnmd-valuation-after-gi-exit-guidance-raise\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At CONMED (CNMD) Valuation After GI Exit, Guidance Raise And Debt Refinancing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At CONMED (CNMD) Valuation After GI Exit, Guidance Raise And Debt Refinancing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-05 21:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/a-look-at-conmed-cnmd-valuation-after-gi-exit-guidance-raise><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/a-look-at-conmed-cnmd-valuation-after-gi-exit-guidance-raise\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/a-look-at-conmed-cnmd-valuation-after-gi-exit-guidance-raise","article_id":"2641145296","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-cnmd/conmed/news/a-look-at-conmed-cnmd-valuation-after-gi-exit-guidance-raise","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2641145296","pubTimestamp":1780666455,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases interest costs but extends financing flexibility.\nSee our latest analysis for CONMED.\nThe refinancing news and portfolio reshaping helped lift the share price, with a 1-day share price return of 6.26%. However, this follows weaker momentum, including a 30-day share price return down 4.12% and a 1-year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","CNMD":"CONMED Corporation","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC"},"translate_title":"GI退出、指导上调和债务再融资后CONMED(CNMD)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CNMD":1.5},"content_text":"CONMED (CNMD) is reshaping its focus after selling its gastrointestinal product portfolio and raising full-year organic growth guidance, while also taking on a new bank term loan that increases interest costs but extends financing flexibility. See our latest analysis for CONMED. The refinancing news and portfolio reshaping helped lift the share price, with a 1-day share price return of 6.26%. However, this follows weaker momentum, including a 30-day share price return down 4.12% and a 1-year total shareholder return down 37.49%. If this kind of medical technology story has your attention, it can be useful to see what else is moving in related areas and uncover 40 healthcare AI stocks With the stock down sharply over 1 and 3 years, yet trading at roughly a 55% discount to one intrinsic value estimate and below the average analyst price target, you have to ask: is this a reset opportunity, or is the market already baking in future growth? AdvertisementMost Popular Narrative: 27.4% Undervalued With CONMED's last close at $35.13 against a narrative fair value of $48.40, the valuation gap is clear and the narrative hangs on a specific earnings and margin path.  Analysts modestly adjusted their price target for CONMED, citing a slightly lower discount rate, unchanged fair value of $48.40, and minimal tweaks to long term growth and P/E assumptions that together fine tune their outlook rather than overhaul it. The limited adjustments to long term growth and P/E assumptions suggest confidence that CONMED can broadly stick to its current execution path without requiring a major reset of expectations.  Read the complete narrative. Want to see the blueprint behind that $48.40 fair value? The narrative leans on steadier revenue progress, higher margins, and a future earnings multiple that is more restrained than many peers. The mix of growth, profitability and discount rate assumptions is all laid out in detail. The tension is how much of that path the market believes today. Result: Fair Value of $48.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, you also have to weigh execution risk. Ongoing supply chain pressures and rising competition are both capable of undermining the earnings and margin path behind that fair value. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page. Next Steps Conflicted by the mix of pressure and potential in the story so far? Take a closer look at the data, form your own view, and weigh up the 3 key rewards and 3 important warning signs. Looking for more investment ideas? If you stop with just one stock, you may miss other opportunities, so use the screener to compare, filter, and build a stronger list of ideas.  Spot potential value opportunities early by scanning 47 high quality undervalued stocks, where pricing and quality line up in a way that may merit a closer look. Prioritize resilience by checking 65 resilient stocks with low risk scores so you can focus on companies that may better match a steadier risk profile. Hunt for under-the-radar potential by reviewing the screener containing 22 high quality undiscovered gems before others catch on.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}